Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dependovirus | 29 | 2026 | 746 | 4.120 |
Why?
|
| Genetic Therapy | 32 | 2026 | 836 | 3.970 |
Why?
|
| Genetic Vectors | 25 | 2026 | 918 | 3.330 |
Why?
|
| Tay-Sachs Disease | 7 | 2025 | 52 | 3.100 |
Why?
|
| Sheep | 11 | 2025 | 191 | 1.900 |
Why?
|
| Sandhoff Disease | 11 | 2025 | 36 | 1.890 |
Why?
|
| Gangliosidosis, GM1 | 6 | 2026 | 26 | 1.570 |
Why?
|
| beta-Hexosaminidase alpha Chain | 3 | 2025 | 20 | 1.520 |
Why?
|
| Disease Models, Animal | 22 | 2025 | 2307 | 1.360 |
Why?
|
| Brain | 15 | 2026 | 1607 | 1.310 |
Why?
|
| Central Nervous System | 11 | 2024 | 200 | 1.220 |
Why?
|
| Cats | 19 | 2024 | 92 | 1.050 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2026 | 2250 | 1.020 |
Why?
|
| Transduction, Genetic | 6 | 2021 | 245 | 0.960 |
Why?
|
| Huntington Disease | 3 | 2023 | 161 | 0.940 |
Why?
|
| Hexosaminidase A | 1 | 2025 | 6 | 0.930 |
Why?
|
| Cerebellopontine Angle | 1 | 2024 | 9 | 0.870 |
Why?
|
| Animals | 45 | 2026 | 21587 | 0.860 |
Why?
|
| Cisterna Magna | 2 | 2024 | 17 | 0.830 |
Why?
|
| Gene Transfer Techniques | 6 | 2024 | 327 | 0.830 |
Why?
|
| Gangliosidoses, GM2 | 4 | 2025 | 19 | 0.810 |
Why?
|
| beta-Hexosaminidase beta Chain | 2 | 2025 | 8 | 0.770 |
Why?
|
| Green Fluorescent Proteins | 1 | 2024 | 378 | 0.770 |
Why?
|
| Gene Expression | 5 | 2025 | 867 | 0.710 |
Why?
|
| beta-N-Acetylhexosaminidases | 6 | 2020 | 20 | 0.690 |
Why?
|
| White Matter | 1 | 2022 | 125 | 0.650 |
Why?
|
| Injections | 1 | 2020 | 84 | 0.640 |
Why?
|
| Thalamus | 1 | 2020 | 76 | 0.610 |
Why?
|
| Biomarkers | 5 | 2023 | 1474 | 0.510 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2020 | 303 | 0.490 |
Why?
|
| Tissue Distribution | 4 | 2024 | 295 | 0.460 |
Why?
|
| Cat Diseases | 3 | 2023 | 19 | 0.460 |
Why?
|
| beta-Galactosidase | 5 | 2026 | 84 | 0.410 |
Why?
|
| Transgenes | 4 | 2022 | 199 | 0.380 |
Why?
|
| Capsid Proteins | 3 | 2021 | 106 | 0.380 |
Why?
|
| Humans | 30 | 2026 | 65551 | 0.380 |
Why?
|
| G(M2) Ganglioside | 4 | 2025 | 16 | 0.360 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2024 | 149 | 0.360 |
Why?
|
| Neurodegenerative Diseases | 2 | 2023 | 149 | 0.330 |
Why?
|
| Phenotype | 2 | 2024 | 1242 | 0.250 |
Why?
|
| Spastin | 1 | 2025 | 6 | 0.240 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2025 | 13 | 0.240 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2025 | 14 | 0.230 |
Why?
|
| Lysophospholipids | 1 | 2025 | 26 | 0.230 |
Why?
|
| Cerebrospinal Fluid | 1 | 2025 | 29 | 0.230 |
Why?
|
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2025 | 9 | 0.220 |
Why?
|
| G(M2) Activator Protein | 1 | 2024 | 2 | 0.220 |
Why?
|
| Maple Syrup Urine Disease | 1 | 2025 | 20 | 0.220 |
Why?
|
| Methotrexate | 1 | 2025 | 83 | 0.220 |
Why?
|
| Vascular Diseases | 1 | 2025 | 83 | 0.220 |
Why?
|
| Huntingtin Protein | 3 | 2023 | 149 | 0.220 |
Why?
|
| Genes, Reporter | 3 | 2019 | 261 | 0.210 |
Why?
|
| Precision Medicine | 2 | 2023 | 127 | 0.210 |
Why?
|
| RNA, Small Interfering | 2 | 2021 | 971 | 0.210 |
Why?
|
| Lysosomes | 4 | 2025 | 171 | 0.210 |
Why?
|
| Blood-Brain Barrier | 2 | 2025 | 87 | 0.200 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2023 | 6 | 0.200 |
Why?
|
| Skin Abnormalities | 1 | 2023 | 8 | 0.200 |
Why?
|
| Mutation | 5 | 2025 | 2691 | 0.200 |
Why?
|
| Contrast Media | 1 | 2026 | 433 | 0.200 |
Why?
|
| Neuroimaging | 1 | 2024 | 159 | 0.190 |
Why?
|
| Prodromal Symptoms | 1 | 2023 | 13 | 0.190 |
Why?
|
| Neurofilament Proteins | 1 | 2023 | 25 | 0.190 |
Why?
|
| Animals, Genetically Modified | 2 | 2023 | 310 | 0.190 |
Why?
|
| Mice | 11 | 2026 | 11251 | 0.190 |
Why?
|
| Anticonvulsants | 2 | 2022 | 103 | 0.190 |
Why?
|
| Catheters | 2 | 2019 | 78 | 0.190 |
Why?
|
| Homeostasis | 1 | 2025 | 379 | 0.180 |
Why?
|
| Mutant Proteins | 1 | 2022 | 106 | 0.170 |
Why?
|
| CRISPR-Cas Systems | 1 | 2025 | 376 | 0.170 |
Why?
|
| Male | 12 | 2026 | 31082 | 0.170 |
Why?
|
| Gene Editing | 1 | 2025 | 333 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2020 | 24 | 0.170 |
Why?
|
| C9orf72 Protein | 1 | 2021 | 114 | 0.170 |
Why?
|
| Growth Plate | 1 | 2020 | 14 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 153 | 0.160 |
Why?
|
| Antigens, Ly | 1 | 2019 | 44 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2020 | 78 | 0.150 |
Why?
|
| Injections, Spinal | 1 | 2019 | 47 | 0.150 |
Why?
|
| Cryotherapy | 1 | 2019 | 16 | 0.150 |
Why?
|
| Phosphoproteins | 1 | 2020 | 223 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 39 | 0.150 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2019 | 57 | 0.150 |
Why?
|
| Cerebral Cortex | 1 | 2020 | 271 | 0.150 |
Why?
|
| Video Recording | 1 | 2019 | 141 | 0.150 |
Why?
|
| Polysaccharides | 1 | 2020 | 154 | 0.150 |
Why?
|
| Models, Animal | 1 | 2019 | 241 | 0.150 |
Why?
|
| Injections, Intraventricular | 3 | 2025 | 23 | 0.140 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2019 | 87 | 0.140 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 628 | 0.130 |
Why?
|
| Microglia | 2 | 2017 | 254 | 0.130 |
Why?
|
| Hypocalcemia | 1 | 2017 | 19 | 0.130 |
Why?
|
| Electroencephalography | 1 | 2017 | 153 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2017 | 296 | 0.120 |
Why?
|
| Disease Progression | 5 | 2025 | 1216 | 0.120 |
Why?
|
| Viral Tropism | 1 | 2016 | 53 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2026 | 2070 | 0.120 |
Why?
|
| Animal Structures | 1 | 2015 | 6 | 0.110 |
Why?
|
| Mucopolysaccharidoses | 1 | 2015 | 4 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2019 | 424 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2026 | 5818 | 0.110 |
Why?
|
| Muscles | 1 | 2016 | 180 | 0.110 |
Why?
|
| Child | 4 | 2026 | 4668 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2015 | 131 | 0.110 |
Why?
|
| G(M1) Ganglioside | 2 | 2026 | 12 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2022 | 823 | 0.110 |
Why?
|
| Echocardiography | 1 | 2017 | 511 | 0.100 |
Why?
|
| Gangliosides | 3 | 2022 | 19 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2019 | 929 | 0.100 |
Why?
|
| Female | 7 | 2026 | 34130 | 0.100 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 277 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 107 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1641 | 0.090 |
Why?
|
| Drug Administration Routes | 2 | 2021 | 22 | 0.090 |
Why?
|
| Peptides | 1 | 2015 | 603 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 1672 | 0.090 |
Why?
|
| Primates | 2 | 2021 | 54 | 0.080 |
Why?
|
| Infant | 2 | 2025 | 1704 | 0.080 |
Why?
|
| Stroke | 1 | 2019 | 1216 | 0.080 |
Why?
|
| Astrocytes | 2 | 2020 | 122 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1310 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 1 | 2026 | 35 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2026 | 46 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2026 | 48 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2026 | 177 | 0.060 |
Why?
|
| Infusions, Intraventricular | 1 | 2025 | 12 | 0.060 |
Why?
|
| Aged | 1 | 2022 | 14963 | 0.060 |
Why?
|
| Gadolinium | 1 | 2026 | 110 | 0.060 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2024 | 10 | 0.060 |
Why?
|
| Atrophy | 1 | 2025 | 87 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2025 | 190 | 0.050 |
Why?
|
| Cattle | 1 | 2025 | 321 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2021 | 1588 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2024 | 59 | 0.050 |
Why?
|
| Adolescent | 2 | 2025 | 6362 | 0.050 |
Why?
|
| Actins | 1 | 2025 | 263 | 0.050 |
Why?
|
| Collagen Type V | 1 | 2023 | 2 | 0.050 |
Why?
|
| Neurons | 2 | 2021 | 949 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2023 | 47 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2023 | 87 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 130 | 0.050 |
Why?
|
| Collagen | 1 | 2023 | 134 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 149 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2022 | 44 | 0.040 |
Why?
|
| Motor Activity | 1 | 2024 | 346 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 91 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2025 | 1157 | 0.040 |
Why?
|
| Quality of Life | 2 | 2022 | 1271 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 91 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2020 | 27 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 82 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2021 | 236 | 0.040 |
Why?
|
| Liver | 1 | 2025 | 879 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2026 | 2509 | 0.040 |
Why?
|
| Swine, Miniature | 1 | 2020 | 10 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2020 | 67 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 272 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2021 | 421 | 0.040 |
Why?
|
| Half-Life | 1 | 2019 | 81 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 79 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 316 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 150 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 164 | 0.040 |
Why?
|
| Hypothermia, Induced | 1 | 2019 | 43 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 349 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2019 | 118 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 2019 | 68 | 0.040 |
Why?
|
| Swine | 1 | 2020 | 397 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 178 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 376 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 238 | 0.040 |
Why?
|
| Dogs | 1 | 2019 | 343 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 3490 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 680 | 0.030 |
Why?
|
| Gliosis | 1 | 2016 | 28 | 0.030 |
Why?
|
| Genes, MHC Class II | 1 | 2016 | 37 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 743 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1049 | 0.030 |
Why?
|
| Cricetulus | 1 | 2015 | 101 | 0.030 |
Why?
|
| CHO Cells | 1 | 2015 | 190 | 0.030 |
Why?
|
| Sulfoglycosphingolipids | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cerebrosides | 1 | 2015 | 4 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 524 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2014 | 39 | 0.030 |
Why?
|
| Young Adult | 1 | 2025 | 4816 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 906 | 0.030 |
Why?
|
| Breeding | 1 | 2014 | 29 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 507 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2015 | 208 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 440 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 199 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 248 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2016 | 794 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 590 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 3344 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 1177 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 2071 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1574 | 0.020 |
Why?
|
| United States | 1 | 2022 | 8128 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 1558 | 0.020 |
Why?
|
| Adult | 1 | 2025 | 17408 | 0.020 |
Why?
|